Filing Details

Accession Number:
0001209191-17-064229
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2017-12-06 17:40:42
Reporting Period:
2017-11-15
Accepted Time:
2017-12-06 17:40:42
Original Submission Date:
2017-11-17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1557290 A Stuart Arbuckle C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp\Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-11-15 48 $147.29 41,952 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 140 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
  2. This amendment corrects an error by our external equity plan administrator and reduces the number of shares sold from 221 shares to 48 shares.